Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Gastrointestinal Stromal Tumors 1

Interventions

Imatinib Mesylate 19Sunitinib 9nilotinib 4ripretinib 3regorafenib 2masitinib 2tanespimycin 1famitinib 1avapritinib 1Sodium Chloride 1Midazolam 1Mastectomy, Segmental 1Immunoglobulin G 1IDRX-42 1Fentanyl 1Disulfides 1Carnitine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × tanespimycin × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡